BriaCell Therapeutics Corp.
Biotechnology ResearchView the employees at
BriaCell Therapeutics Corp.-
Lynn Frederick Head of Quality Assurance
-
Williamstown, New Jersey, United States
-
Rising Star
Blaise B. Clinical Trials Research and Operations Associate | MD, BS-
Tomball, Texas, United States
-
Top 10%
Gadi Levin Director and senior executive-
Tel Aviv District
-
Top 10%
Vaughn Embro-Pantalony MBA, FCPA, FCMA, C.Dir, ACC Independent Director, CEO, CFO, CIO in Life Sciences-
Greater Toronto Area, Canada
-
Rising Star
Overview
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer. For additional information on BriaCell, please visit our website: http://briacell.com/
-